UPM Pharmaceuticals Awarded UPM Pharmaceutica
Post# of 223
Posted On: 04/29/2015 8:29:58 PM
UPM Pharmaceuticals Awarded
UPM Pharmaceuticals Awarded The 2015 Industry Choice Award For Mid-sized And Emerging Pharma
NOTE: UPM Pharmaceuticals To Manufacture BioPharmX's First Commercially Available Product
BRISTOL, Tenn., April 28, 2015 /PRNewswire/ -- UPM Pharmaceuticals, an independent drug contract development and manufacturing organization (CDMO), was awarded the prestigious "2015 Industry Choice Award" in the Mid-sized and Emerging Pharma sector. The award was presented by Life Science Leader magazine during the annual CMO Leadership Awards Ceremony and Reception in New York City on March 18, 2015. The CMO Leadership Awards are designed to honor top performing service organizations based on survey responses from thousands of pharmaceutical and biotechnology industry executives collected annually by Nice Insight. The Industry Choice Awards were determined by averaging the perception scores of each CMO across the buying group categories and then ranking the results. In other words, UPM ranked highest in industry perception scores amongst all service providers that perform work for the Mid-sized and Emerging Pharma sector. Additionally, UPM was recognized for the 4th consecutive year as a category winner (5 in all) in the distinct areas of Innovation, Productivity, Quality, Regulatory and Reliability. UPM is honored to be the best of the best of these organizations as an Industry Choice Award recipient.
UPM Pharmaceuticals Inc.
"To be awarded the Industry Choice Award and recognized as the top company for 2015 in the Mid-Sized and Emerging Pharma sector is truly an honor for the UPM team. This further validates our proven history of excellence and client satisfaction within the industry. This is a phenomenal achievement for our company and is attributed to the hard work and dedication of our highly skilled employees. They are driven by their commitment to succeed in developing and manufacturing the foremost quality products and providing our clients with the confidence that we are worthy stewards of their development projects," said Jim Gregory, CEO.
At UPM Pharmaceuticals, scientific sophistication and experience come together with flexibility, responsiveness and innovation. UPM is a CDMO providing pharmaceutical drug development services, including formulation development, GMP clinical and commercial manufacturing, analytical methods development, stability testing, packaging and warehousing.
Our drug development services are characterized by a core commitment to meeting the client's objectives with the highest quality, while maintaining the most efficient use of time and controlling costs. Our pharmaceutical development team applies its extensive experience as an award-winning CMO in developing creative solutions to your unique challenges. UPM takes enormous pride in supporting pharmaceutical companies at every step of the drug development process.
Dating back to the early 1990's UPM has strived to provide the highest quality research and development. Now, with its new 475,000 square feet commercial manufacturing facility, we strive to become a full-service leader in the CDMO pharmaceutical industry.
UPM Pharmaceuticals Awarded The 2015 Industry Choice Award For Mid-sized And Emerging Pharma
NOTE: UPM Pharmaceuticals To Manufacture BioPharmX's First Commercially Available Product
BRISTOL, Tenn., April 28, 2015 /PRNewswire/ -- UPM Pharmaceuticals, an independent drug contract development and manufacturing organization (CDMO), was awarded the prestigious "2015 Industry Choice Award" in the Mid-sized and Emerging Pharma sector. The award was presented by Life Science Leader magazine during the annual CMO Leadership Awards Ceremony and Reception in New York City on March 18, 2015. The CMO Leadership Awards are designed to honor top performing service organizations based on survey responses from thousands of pharmaceutical and biotechnology industry executives collected annually by Nice Insight. The Industry Choice Awards were determined by averaging the perception scores of each CMO across the buying group categories and then ranking the results. In other words, UPM ranked highest in industry perception scores amongst all service providers that perform work for the Mid-sized and Emerging Pharma sector. Additionally, UPM was recognized for the 4th consecutive year as a category winner (5 in all) in the distinct areas of Innovation, Productivity, Quality, Regulatory and Reliability. UPM is honored to be the best of the best of these organizations as an Industry Choice Award recipient.
UPM Pharmaceuticals Inc.
"To be awarded the Industry Choice Award and recognized as the top company for 2015 in the Mid-Sized and Emerging Pharma sector is truly an honor for the UPM team. This further validates our proven history of excellence and client satisfaction within the industry. This is a phenomenal achievement for our company and is attributed to the hard work and dedication of our highly skilled employees. They are driven by their commitment to succeed in developing and manufacturing the foremost quality products and providing our clients with the confidence that we are worthy stewards of their development projects," said Jim Gregory, CEO.
At UPM Pharmaceuticals, scientific sophistication and experience come together with flexibility, responsiveness and innovation. UPM is a CDMO providing pharmaceutical drug development services, including formulation development, GMP clinical and commercial manufacturing, analytical methods development, stability testing, packaging and warehousing.
Our drug development services are characterized by a core commitment to meeting the client's objectives with the highest quality, while maintaining the most efficient use of time and controlling costs. Our pharmaceutical development team applies its extensive experience as an award-winning CMO in developing creative solutions to your unique challenges. UPM takes enormous pride in supporting pharmaceutical companies at every step of the drug development process.
Dating back to the early 1990's UPM has strived to provide the highest quality research and development. Now, with its new 475,000 square feet commercial manufacturing facility, we strive to become a full-service leader in the CDMO pharmaceutical industry.
(0)
(0)